{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T23:28:31Z","timestamp":1788305311699,"version":"build-2803163510"},"reference-count":72,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.ejps.2020.105260","type":"journal-article","created":{"date-parts":[[2020,2,10]],"date-time":"2020-02-10T11:43:15Z","timestamp":1581334995000},"page":"105260","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Development of a minimal physiologically-based pharmacokinetic\/pharmacodynamic model to characterize target cell depletion and cytokine release for T cell-redirecting bispecific agents in humans"],"prefix":"10.1016","volume":"146","author":[{"given":"Xiling","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pharavee","family":"Jaiprasart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Carpenter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weirong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2020.105260_bib0001","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s11912-019-0753-y","article-title":"Cytokine release syndrome with the novel treatments of acute lymphoblastic leukemia: pathophysiology, prevention, and treatment","volume":"21","author":"Aldoss","year":"2019","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.ejps.2020.105260_bib0002","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/nrc3907","article-title":"Haematological malignancies: at the forefront of immunotherapeutic innovation","volume":"15","author":"Bachireddy","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejps.2020.105260_bib0003","doi-asserted-by":"crossref","first-page":"5144","DOI":"10.1182\/blood-2019-127138","article-title":"Improvement in cytokine release syndrome management for the treatment of AML patients with flotetuzumab, a CD123 x CD3 bispecific dart\u00ae molecule for T-cell redirected therapy","volume":"134","author":"Bakkacha","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.ejps.2020.105260_bib0004","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1126\/science.1158545","article-title":"Tumor regression in cancer patients by very low doses of a T cell-engaging antibody","volume":"321","author":"Bargou","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.ejps.2020.105260_bib0005","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1208\/s12248-019-0332-z","article-title":"A Translational quantitative systems pharmacology model for CD3 bispecific molecules: application to quantify T cell-mediated tumor cell killing by P-cadherin LP DART((R))","volume":"21","author":"Betts","year":"2019","journal-title":"AAPS J."},{"key":"10.1016\/j.ejps.2020.105260_bib0006","doi-asserted-by":"crossref","first-page":"184","DOI":"10.3389\/fimmu.2016.00184","article-title":"A T cell view of the bone marrow","volume":"7","author":"Bonomo","year":"2016","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejps.2020.105260_bib0007","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1177\/074823379701300401","article-title":"Physiological parameter values for physiologically based pharmacokinetic models","volume":"13","author":"Brown","year":"1997","journal-title":"Toxicol. Ind. Health"},{"key":"10.1016\/j.ejps.2020.105260_bib0008","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1158\/1078-0432.CCR-17-2265","article-title":"Integrated pharmacokinetic\/pharmacodynamic model of a bispecific CD3xCD123 DART(R) molecule in nonhuman primates: evaluation of activity and impact of immunogenicity","volume":"24","author":"Campagne","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejps.2020.105260_bib0009","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s10928-013-9332-2","article-title":"Second-generation minimal physiologically-based pharmacokinetic model for monoclonal antibodies","volume":"40","author":"Cao","year":"2013","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"10.1016\/j.ejps.2020.105260_bib0010","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s10928-014-9374-0","article-title":"Survey of monoclonal antibody disposition in man utilizing a minimal physiologically-based pharmacokinetic model","volume":"41","author":"Cao","year":"2014","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"10.1016\/j.ejps.2020.105260_bib0011","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/j.1432-1033.1988.tb14383.x","article-title":"Plasma clearance, organ distribution and target cells of interleukin-6\/hepatocyte-stimulating factor in the rat","volume":"177","author":"Castell","year":"1988","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.ejps.2020.105260_bib0012","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1002\/cpt.393","article-title":"Mechanistic Projection of First-in-Human Dose for Bispecific Immunomodulatory P-Cadherin LP-DART: an Integrated PK\/PD Modeling Approach","volume":"100","author":"Chen","year":"2016","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2020.105260_bib0013","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s10928-016-9472-2","article-title":"Minimal physiologically-based pharmacokinetic (mPBPK) model for a monoclonal antibody against interleukin-6 in mice with collagen-induced arthritis","volume":"43","author":"Chen","year":"2016","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"10.1016\/j.ejps.2020.105260_bib0014","doi-asserted-by":"crossref","DOI":"10.1111\/cts.12662","article-title":"A Modeling Framework to Characterize Cytokine Release upon T cell-engaging Bispecific Antibody Treatment: methodology and opportunities","author":"Chen","year":"2019","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.ejps.2020.105260_bib0015","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification.","volume":"32","author":"Cheson","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejps.2020.105260_bib0016","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaa5693","article-title":"A CD3xCD123 bispecific DART for redirecting host T cells to myelogenous leukemia: preclinical activity and safety in nonhuman primates","volume":"7","author":"Chichili","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ejps.2020.105260_bib0017","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ymeth.2018.10.026","article-title":"Bispecific T-cell engagers: towards understanding variables influencing the in vitro potency and tumor selectivity and their modulation to enhance their efficacy and safety","volume":"154","author":"Ellerman","year":"2019","journal-title":"Methods"},{"key":"10.1016\/j.ejps.2020.105260_bib0018","doi-asserted-by":"crossref","first-page":"4356","DOI":"10.1128\/iai.61.10.4356-4359.1993","article-title":". Differential regulation of cytokine production in lipopolysaccharide tolerance in mice","volume":"61","author":"Erroi","year":"1993","journal-title":"Infect. Immun."},{"key":"10.1016\/j.ejps.2020.105260_bib0019","unstructured":"U. S. Food and Drug Administration. Center for Drug Evaluation and Research. (2019). Bispecific Antibody Development Programs Guidance for Industry."},{"key":"10.1016\/j.ejps.2020.105260_bib0020","doi-asserted-by":"crossref","unstructured":"Fiedler, W.M., Wolf, M., Kebenko, M., Goebeler, M.-E., Ritter, B., Quaas, A., Vieser, E., Hijazi, Y., Patzak, I., Friedrich, M., Kufer, P., Frankel, S., Seggewiss-Bernhardt, R., Kaubitzsch, S., 2012. A phase I study of EpCAM\/CD3-bispecific antibody (MT110) in patients with advanced solid tumors. 30, 2504-2504.","DOI":"10.1200\/jco.2012.30.15_suppl.2504"},{"key":"10.1016\/j.ejps.2020.105260_bib0021","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1182\/asheducation-2016.1.567","article-title":"Cytokine release syndrome with novel therapeutics for acute lymphoblastic leukemia","volume":"2016","author":"Frey","year":"2016","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program."},{"key":"10.1016\/j.ejps.2020.105260_bib0022","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1177\/0141076809701003","article-title":"Adult bone-marrow stem cells and their potential in medicine","volume":"97","author":"Hassan","year":"2004","journal-title":"J. R. Soc. Med."},{"key":"10.1016\/j.ejps.2020.105260_bib0023","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2174\/1574884713666180518102514","article-title":"Pharmacokinetic and pharmacodynamic relationship of blinatumomab in patients with non-Hodgkin lymphoma","volume":"13","author":"Hijazi","year":"2018","journal-title":"Curr. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2020.105260_bib0024","series-title":"The eighth American conference on pharmacometrics","article-title":"Systems pharmacology modeling to support clinical development of anti-CD20\/CD3 T-cell dependent bispecific antibody","author":"Hosseini","year":"2016"},{"key":"10.1016\/j.ejps.2020.105260_bib0025","doi-asserted-by":"crossref","first-page":"6487","DOI":"10.1158\/1078-0432.CCR-08-1086","article-title":"Identification of a novel tumor-associated antigen, cadherin 3\/P-cadherin, as a possible target for immunotherapy of pancreatic, gastric, and colorectal cancers","volume":"14","author":"Imai","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejps.2020.105260_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2019.114657","article-title":"Daily ascending dosing in cynomolgus monkeys to mitigate cytokine release syndrome induced by ERY22, surrogate for T-cell redirecting bispecific antibody ERY974 for cancer immunotherapy","volume":"379","author":"Iwata","year":"2019","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.ejps.2020.105260_bib0028","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1080\/19420862.2018.1480299","article-title":"Development of a Target cell-Biologics-Effector cell (TBE) complex-based cell killing model to characterize target cell depletion by T cell redirecting bispecific agents","volume":"10","author":"Jiang","year":"2018","journal-title":"MAbs"},{"key":"10.1016\/j.ejps.2020.105260_bib0029","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejps.2020.105260_bib0030","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.cmpb.2010.04.018","article-title":"Pirana and PCluster: a modeling environment and cluster infrastructure for NONMEM","volume":"101","author":"Keizer","year":"2011","journal-title":"Comput. Methods Programs Biomed."},{"key":"10.1016\/j.ejps.2020.105260_bib0031","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/imr.12393","article-title":"Harnessing T cells to fight cancer with BiTE(R) antibody constructs\u2013past developments and future directions","volume":"270","author":"Klinger","year":"2016","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.ejps.2020.105260_bib0032","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1038\/leu.2015.214","article-title":"Blockade of the PD-1\/PD-L1 axis augments lysis of AML cells by the CD33\/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism","volume":"30","author":"Krupka","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.ejps.2020.105260_bib0033","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.ccell.2017.02.001","article-title":"Membrane-proximal epitope facilitates efficient T cell synapse formation by anti-FcRH5\/CD3 and is a requirement for myeloma cell killing","volume":"31","author":"Li","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejps.2020.105260_bib0034","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.cmpb.2005.04.005","article-title":"PsN-Toolkit\u2013a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM","volume":"79","author":"Lindbom","year":"2005","journal-title":"Comput. Methods Programs Biomed."},{"key":"10.1016\/j.ejps.2020.105260_bib0035","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1182\/blood.V86.8.3123.3123","article-title":"Measurement of whole body interleukin-6 (IL-6) production: prediction of the efficacy of anti-IL-6 treatments","volume":"86","author":"Lu","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.ejps.2020.105260_bib0036","doi-asserted-by":"crossref","first-page":"365","DOI":"10.2165\/11595950-000000000-00000","article-title":"Targeting T cells with bispecific antibodies for cancer therapy","volume":"25","author":"Lum","year":"2011","journal-title":"BioDrugs"},{"key":"10.1016\/j.ejps.2020.105260_bib0037","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1007\/s00280-015-2728-5","article-title":"A phase I trial of intravenous catumaxomab: a bispecific monoclonal antibody targeting EpCAM and the T cell coreceptor CD3","volume":"75","author":"Mau-Sorensen","year":"2015","journal-title":"Cancer Chemother Pharmacol."},{"key":"10.1016\/j.ejps.2020.105260_bib0038","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/s41408-017-0023-x","article-title":"CD19-negative relapse of pediatric B-cell precursor acute lymphoblastic leukemia following blinatumomab treatment","volume":"7","author":"Mejstrikova","year":"2017","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.ejps.2020.105260_bib0039","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.3892\/or.2017.5387","article-title":"Biology and function of glypican-3 as a candidate for early cancerous transformation of hepatocytes in hepatocellular carcinoma (Review)","volume":"37","author":"Montalbano","year":"2017","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.ejps.2020.105260_bib0040","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/nature12984","article-title":"The bone marrow niche for haematopoietic stem cells","volume":"505","author":"Morrison","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.ejps.2020.105260_bib0041","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s40164-017-0074-5","article-title":"Changes in clinical laboratory parameters and pharmacodynamic markers in response to blinatumomab treatment of patients with relapsed\/refractory ALL","volume":"6","author":"Nagele","year":"2017","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.ejps.2020.105260_bib0027","doi-asserted-by":"crossref","unstructured":"Jacobs, K., Godwin, J., Foster, M., Vey, N., Uy, G.L., Rizzieri, D.A., Arellano, M.L., Rettig, M.P., Christ, S., Topp, M.S., Huls, G., Lowenberg, B., Martinelli, G., Paolini, S., Ciceri, F., Carrabba, M.G., Sun, J., Li, D., Tran, K., Spohn, K., Baughman, J., Shankar, S., Leli\u00e8vre, H., Bonvini, E., DiPersio, J.F., Wigginton, J., davidson-Moncada, J.K., 2017. Lead-in dose optimization to mitigate cytokine release syndrome in AML and MDS patients treated with flotetuzumab, a CD123 x CD3 Dart\u00ae molecule for T-cell redirected therapy. Blood 2017; 130 (Supplement 1): 3856.","DOI":"10.1182\/blood-2018-99-112615"},{"key":"10.1016\/j.ejps.2020.105260_bib0042","doi-asserted-by":"crossref","unstructured":"Ravandi, F., Stein, A.S., Kantarjian, H.M., Walter, R.B., Paschka, P., Jongen-Lavrencic, M., Ossenkoppele, G.J., Yang, Z., Mehta, B., Subklewe, M., 2018. A phase 1 first-in-human study of AMG 330, an anti-CD33 bispecific T-cell engager (BiTE\u00ae) antibody construct, in Relapsed\/Refractory Acute Myeloid Leukemia (R\/R AML). 132, 25-25.","DOI":"10.1182\/blood-2018-99-109762"},{"key":"10.1016\/j.ejps.2020.105260_bib0043","first-page":"121","article-title":"Structural features of bone marrow","volume":"8","author":"Romaniuk","year":"2016","journal-title":"Interv. Med. Appl. Sci."},{"key":"10.1016\/j.ejps.2020.105260_bib0044","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.yrtph.2017.09.001","article-title":"An FDA oncology analysis of CD3 bispecific constructs and first-in-human dose selection","volume":"90","author":"Saber","year":"2017","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.ejps.2020.105260_bib0045","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.yrtph.2016.10.002","article-title":"An FDA oncology analysis of immune activating products and first-in-human dose selection","volume":"81","author":"Saber","year":"2016","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.ejps.2020.105260_bib0046","doi-asserted-by":"crossref","first-page":"e8933","DOI":"10.1371\/journal.pone.0008933","article-title":"The average body surface area of adult cancer patients in the UK: a multicentre retrospective study","volume":"5","author":"Sacco","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.ejps.2020.105260_bib0047","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/1043-4666(94)90040-X","article-title":"Elevation of circulating interleukin 6 after surgery: factors influencing the serum level","volume":"6","author":"Sakamoto","year":"1994","journal-title":"Cytokine"},{"key":"10.1016\/j.ejps.2020.105260_bib0048","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1097\/PAI.0b013e318294cb61","article-title":"AngioMap is a novel image analysis algorithm for assessment of plasma cell distribution within bone marrow vascular niche","volume":"22","author":"Salama","year":"2014","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"10.1016\/j.ejps.2020.105260_bib0049","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/psp4.12369","article-title":"Target-mediated drug disposition model for bispecific antibodies: properties, approximation, and optimal dosing strategy","volume":"8","author":"Schropp","year":"2019","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"10.1016\/j.ejps.2020.105260_bib0050","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1118\/1.1288393","article-title":"Red marrow dosimetry for radiolabeled antibodies that bind to marrow, bone, or blood components","volume":"27","author":"Sgouros","year":"2000","journal-title":"Med. Phys."},{"key":"10.1016\/j.ejps.2020.105260_bib0051","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s10928-011-9232-2","article-title":"Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human","volume":"39","author":"Shah","year":"2012","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"10.1016\/j.ejps.2020.105260_bib0052","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","article-title":"Cytokine release syndrome","volume":"6","author":"Shimabukuro-Vornhagen","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.ejps.2020.105260_bib0053","doi-asserted-by":"crossref","unstructured":"Strohl, W.R., Naso, M., 2019. Bispecific T-cell redirection versus Chimeric Antigen Receptor (CAR)-T cells as approaches to kill cancer cells. 8, 41.","DOI":"10.3390\/antib8030041"},{"key":"10.1016\/j.ejps.2020.105260_bib0054","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1634\/stemcells.21-3-296","article-title":"Absolute values of dendritic cell subsets in bone marrow, cord blood, and peripheral blood enumerated by a novel method","volume":"21","author":"Szabolcs","year":"2003","journal-title":"Stem. Cells"},{"key":"10.1016\/j.ejps.2020.105260_bib0055","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ccell.2016.02.004","article-title":"Facilitating T cell infiltration in tumor microenvironment overcomes resistance to PD-L1 blockade","volume":"29","author":"Tang","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejps.2020.105260_bib0056","doi-asserted-by":"crossref","unstructured":"Topp, M.S., Duell, J., Zugmaier, G., Attal, M., Moreau, P., Langer, C., Kroenke, J., Facon, T., Salnikov, A., Lesley, R., Beutner, K., Kalabus, J., Rasmussen, E., Riemann, K., Minella, A.C., Munzert, G.M., Einsele, H., 2019. Evaluation of AMG 420, an anti-BCMA bispecific T-cell engager (BiTE) immunotherapy, in R\/R multiple myeloma (MM) patients: updated results of a first-in-human (FIH) phase I dose escalation study. 37, 8007.","DOI":"10.1200\/JCO.2019.37.15_suppl.8007"},{"key":"10.1016\/j.ejps.2020.105260_bib0057","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/cts.12459","article-title":"Clinical Pharmacology and Translational Aspects of Bispecific Antibodies","volume":"10","author":"Trivedi","year":"2017","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.ejps.2020.105260_bib0058","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s10522-017-9707-7","article-title":"Influence of ageing on the microarchitecture of the spleen and lymph nodes","volume":"18","author":"Turner","year":"2017","journal-title":"Biogerontology"},{"key":"10.1016\/j.ejps.2020.105260_bib0059","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1182\/blood-2017-06-741058","article-title":"Redirecting T cells to hematological malignancies with bispecific antibodies","volume":"131","author":"Velasquez","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.ejps.2020.105260_bib0060","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1182\/blood-2015-06-651380","article-title":"Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed\/refractory diffuse large B-cell lymphoma","volume":"127","author":"Viardot","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ejps.2020.105260_bib0061","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/s12943-015-0448-4","article-title":"P-cadherin and the journey to cancer metastasis","volume":"14","author":"Vieira","year":"2015","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ejps.2020.105260_bib0062","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1208\/s12248-013-9545-8","article-title":"Mechanistic pharmacokinetic\/target engagement\/pharmacodynamic (PK\/TE\/PD) modeling in deciphering interplay between a monoclonal antibody and its soluble target in cynomolgus monkeys","volume":"16","author":"Wang","year":"2014","journal-title":"AAPS J."},{"key":"10.1016\/j.ejps.2020.105260_bib0063","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.humpath.2003.08.026","article-title":"Frequent EpCam protein expression in human carcinomas","volume":"35","author":"Went","year":"2004","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.ejps.2020.105260_bib0064","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1182\/blood-2013-03-488411","article-title":"Closing the gap between T-cell life span estimates from stable isotope-labeling studies in mice and humans","volume":"122","author":"Westera","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.ejps.2020.105260_bib0065","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/acel.12311","article-title":"Lymphocyte maintenance during healthy aging requires no substantial alterations in cellular turnover","volume":"14","author":"Westera","year":"2015","journal-title":"Aging Cell"},{"key":"10.1016\/j.ejps.2020.105260_bib0066","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1182\/blood-2017-07-740993","article-title":"PD-1 expression and clinical PD-1 blockade in B-cell lymphomas","volume":"131","author":"Xu-Monette","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.ejps.2020.105260_bib0067","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0216485","article-title":"Understanding heterogeneous tumor microenvironment in metastatic melanoma","volume":"14","author":"Yan","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.ejps.2020.105260_bib0068","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1002\/cpt.651","article-title":"Translation and Clinical Development of Bispecific T-cell Engaging Antibodies for Cancer Treatment","volume":"101","author":"Yuraszeck","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2020.105260_bib0069","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1002\/jcph.1006","article-title":"Blinatumomab Pharmacodynamics and Exposure-Response Relationships in Relapsed\/Refractory Acute Lymphoblastic Leukemia","volume":"58","author":"Zhu","year":"2018","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2020.105260_bib0070","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1007\/s40262-016-0405-4","article-title":"Blinatumomab, a Bispecific T-cell Engager (BiTE((R))) for CD-19 Targeted Cancer Immunotherapy: clinical Pharmacology and Its Implications","volume":"55","author":"Zhu","year":"2016","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejps.2020.105260_bib0071","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.coi.2016.02.006","article-title":"Bispecific antibodies and CARs: generalized immunotherapeutics harnessing T cell redirection","volume":"40","author":"Zhukovsky","year":"2016","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.ejps.2020.105260_bib0072","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1182\/blood-2015-06-649111","article-title":"Long-term survival and T-cell kinetics in relapsed\/refractory ALL patients who achieved MRD response after blinatumomab treatment","volume":"126","author":"Zugmaier","year":"2015","journal-title":"Blood"}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092809872030049X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092809872030049X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T11:52:46Z","timestamp":1760529166000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092809872030049X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":72,"alternative-id":["S092809872030049X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2020.105260","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of a minimal physiologically-based pharmacokinetic\/pharmacodynamic model to characterize target cell depletion and cytokine release for T cell-redirecting bispecific agents in humans","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2020.105260","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105260"}}